70.86MMarket Cap-1.05P/E (TTM)
1.630High1.490Low606.11KVolume1.550Open1.570Pre Close954.60KTurnover2.38%Turnover RatioLossP/E (Static)44.56MShares8.19452wk High0.79P/B40.48MFloat Cap1.38052wk Low--Dividend TTM25.46MShs Float23.990Historical High--Div YieldTTM8.92%Amplitude1.380Historical Low1.574Avg Price1Lot Size
Werewolf Therapeutics Stock Forum
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics (HOWL) presented interim Phase 1 clinical trial results for WTX-330, their tumor-activated IL-12 prodrug, at SITC's 39th Annual Meeting. The trial enrolled 25 patients with diverse solid tumors, showing favorable tolerability and encouraging efficacy. Key findings include a confirmed partial response in a ...
4 mins ago
Werewolf Therapeutics Announces Promising New Development Candidate, Wtx-921, a First-of-Its-Kind Il-10 Indukine™ Molecule for Inflammatory Diseases
📊⚡️📊
📊⚡️📊
No comment yet